Statin associated lower cancer risk and related mortality in patients with heart failure

Abstract

Aims Patients with heart failure (HF) have an increased risk of incident cancer. Data relating to the association of statin use with cancer risk and cancer-related mortality among patients with HF are sparse. Methods and results Using a previously validated territory-wide clinical information registry, statin use was ascertained among all eligible patients with HF (n = 87 102) from 2003 to 2015. Inverse probability of treatment weighting was used to balance baseline covariates between statin nonusers (n = 50 926) with statin users (n = 36 176). Competing risk regression with Cox proportional-hazard models was performed to estimate the risk of cancer and cancer-related mortality associated with statin use. Of all eligible subjects, the mean age was 76.5 ± 12.8 years, and 47.8% was male. Over a median follow-up of 4.1 years (interquartile range: 1.6–6.8), 11 052 (12.7%) were diagnosed with cancer. Statin use (vs. none) was associated with a 16% lower risk of cancer incidence [multivariable adjusted subdistribution hazard ratio (SHR) = 0.84; 95% confidence interval (CI), 0.80–0.89]. This inverse association with risk of cancer was duration dependent; as compared with short-term statin use (3 months to <2 years), the adjusted SHR was 0.99 (95% CI, 0.87–1.13) for 2 to <4 years of use, 0.82 (95% CI, 0.70–0.97) for 4 to <6 years of use, and 0.78 (95% CI, 0.65–0.93) for ≥6 years of use. Ten-year cancer-related mortality was 3.8% among statin users and 5.2% among nonusers (absolute risk difference, −1.4 percentage points [95% CI, −1.6% to −1.2%]; adjusted SHR = 0.74; 95% CI, 0.67–0.81). Conclusion Our study suggests that statin use is associated with a significantly lower risk of incident cancer and cancer-related mortality in HF, an association that appears to be duration dependent.

Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002–2019)

“…The Hospital Authority is the sole public healthcare provider in Hong Kong, covering >80% of secondary and tertiary care in Hong Kong with a population of around 7.5 million. 13 , 14 Patients’ clinical information, including demographics, diagnoses, blood tests, and surgical treatments, were prospectively recorded in CDARS. Previous high-quality population-based studies have validated the coding accuracy of CDARS.…”

Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases

“…There is no proof that statins are beneficial in breast cancer [ 127 , 128 ] although some studies reported a positive role of statins in this type of cancer. Cauley et al showed a lower risk of breast cancer in patients treated with statins [ 129 , 130 ], but the results of six cohort studies [ 128 , 129 , 131 , 132 , 133 , 134 ] and two case-control studies could not support either positive or negative associations between statins and the occurrence of cancer [ 135 , 136 ]. The effect of statins on cell cycle progression may be annulled if statins were used with hormones, especially estrogens [ 132 ].…”

Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study

“…Our study mimicked an intention-to-treat design, where aspirin exposure was defined as ≥90 consecutive cumulative DDD of aspirin beginning at the index date [ 18 , 22 ]. Patients who received aspirin for a period less than 90 consecutive DDD were excluded [ 23 ]. Due to the lack of international standardization of aspirin doses, WHO recommended a dose definition as 1 tablet of aspirin independent of tablet strength [ 24 ].…”